Is Gilead Sciences (GILD) Undervalued After Strong Q2 Sales?

Gilead Sciences stock has delivered a strong multi year run, which puts a spotlight on whether the current share price still lines up with the company’s sales base. With fresh headlines on earnings, partnerships and pipeline progress, the real question for investors is how much of Gilead’s revenue story is already reflected in today’s valuation. Over the past 5 years, Gilead Sciences has returned 167.1%. Anyone looking at the stock now is asking how that kind of gain squares with its sales...